Clinical trials: HLH, active
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
This is a pilot study to gather information about safety and efficacy of using ruxolitinib (RUX) to treat Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) occurring after CAR-T therapy.
- Trial name
- RISE (NCT07424222)
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Hemophagocytic Lymphohistiocytoses
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated…
- Trial name
- NCT05898477
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Alabama at Birmingham
Hemophagocytic Lymphohistiocytosis (HLH)
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.
- Trial name
- NCT06951971
- Testing
- dose-modified E-Ru, Salvage treatment and follow-up
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
HLH, Hemophagocytic Lymphohistiocytoses
Prospective Validation of the OHI Index
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival).
- Conditions
- HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy
- Trial name
- HLH (NCT05882175)
- Where
- 2 sites in Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Hemophagocytic Lymphohistiocytoses
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis
This study is trying to evaluate the efficacy and safety of modified DEP regimens for the treatment of active hemophagocytic lymphohistiocytosis.
- Trial name
- NCT06504030
- Testing
- modified-DEP
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
EBV Infection
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus.
- Trial name
- NCT03491605
- Testing
- peripheral EBV-DNA load
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huazhong University of Science and Technology
Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
- Trial name
- NCT05988177
- Testing
- Carrimycin tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes…
- Trial name
- NCT07525466
- Testing
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Tongren Hospital
EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with…
- Conditions
- EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir
- Trial name
- NCT07488728
- Testing
- Letermovir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Children's Hospital
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or…
- Trial name
- NCT03827343
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Hemophagocytic Lymphohistiocytosis
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures.
- Trial name
- TIC-TAC-SAM (NCT07497438)
- Testing
- Etoposide (Early strategy), Etoposide (Delayed strategy)
- Where
- France
- Volunteers
- 176 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
- Trial name
- HAPLOTAB (NCT05236764)
- Testing
- CliniMACS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
The Microbiome in Blood Cancer and HLH
The bacteria and viruses in the bowel (gut microbiota; GM) have powerful effects on the immune system. GM changes are seen in patients with auto-immune diseases, where the immune system attacks normal tissues, and cancer, and for…
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Haemophagocytic Lymphohistiocytosis
- Trial name
- NCT06734624
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- University of Nottingham
Lymphohistiocytosis, Hemophagocytic
Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.
- Trial name
- NCT07339345
- Testing
- Golidocitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore…
- Conditions
- Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
- Trial name
- NCT06131489
- Testing
- Segmental bowel resection combined with the DEP regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
HLH, Hemophagocytic Lymphohistiocytoses
Establishing a National Egyptian HLH Registry (NEHR)
Establishing a National Egyptian HLH Registry (NEHR)
- Trial name
- NEHR (NCT07800234)
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Infertility
Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment
This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under…
- Trial name
- NCT06571214
- Testing
- Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®), Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Nanjing University
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota